Data utility. We expect that the data based on full omics profiling of patients will be used by clinicians in clinical decision making. Based on similarities of drugs and drug targets, we attempt to predict statistically the synergy of drug combinations at various doses, which should be of interest for drug developing companies. • Prospective and retrospective clinical data: Ethical permits and data protection regulations limit the amount of clinical data that can be shared outside the project, but the data that can be shared through publications and repositories in connection with e.g., the sequencing data are extremely useful for other ovarian cancer researchers. • Most sequencing data from prospective patient samples, including organoids, are also subject to ethical and data protection regulations, but will be a valuable resource to other (ovarian) cancer researchers after they are archived to a controlled access data repository European Genome Phenome Archive (EGA). • One of the features in DECIDER is to conduct a Dream Challenge competition in which anonymised data will be used. These data will be freely available and useful for method developers participating in the challenge. • Sequencing data from retrospective patient samples will be stored to biobank, which allows the use of it for other researchers. • Sequencing data from commercial cell lines: WGS data and the genetic screening data are anticipated to be made available as mutation calls (WGS) and read counts (screening), deposited in repositories such as FigShare or Dryad or similar. This should be useful to human genomics researchers and to cancer researchers. • Sequencing data from commercial ctDNA reference standards and commercial ctDNA reference standards spiked-in into blood samples from healthy donors: the data are useful only for performance verification of assays developed within the project. • Imaging data from PET/CT scans: The images are not shared but features, such as tumour volume and locations of the masses will be. These are useful for mathematicians who develop models for tumour progression. • Imaging data from histopathological slides of prospective samples: Histopathological images will be available from a constrained repository in which the Data Access Committee can ensure that the research questions are in line with the patient consent. The consortium is looking into possible repository options as histopathological image repositories at the moment are scarce. An option is to utilise the...
Data utility. Gloo’s Data Utilities enable the Company to access and use data and other information obtained from certain Users regarding their access to and use of the Infrastructure and the Company Platform (“User Data”) as may be further set forth in Order Form and SOWs. In connection with the Infrastructure Services, Gloo may collect, access, and use User Data in accordance with the Terms of Service and Privacy Policy in effect at the time the User Data is collected. To the extent not otherwise provided by the Users, Company grants Gloo all rights and licenses necessary to collect, access, and use the User Data obtained from Users accessing the Company Platform and other Infrastructure on behalf of Users in accordance with the Terms of Service and Privacy Policy. Company’s use of User Data, if any, must comply with with all laws and regulations as well as be consistent with the permitted uses in Gloo’s Terms of Service and Privacy Policy.
Data utility. Except the internal needs to use the dataset (in order to develop SerIoT component e.g. monitoring application for C-ITS Road Side Stations, and test them), the data may be useful for research purposes in future projects, which have interest in IoT devices and Cyber-security. Moreover, the dataset will include data related to automated transport, and will be useful to researchers in automated transport more focused on secure communications for safety.
Data utility. In general, the audience who might use data generated or collected in the project POLYPHEM are: The POLYPHEM Consortium; European Commission services, European Agencies, EU and national policy makers; Research institutions, universities, institutes, training centers across the Europe and worldwide; CSP and renewable energies related industries; Private and public investment sector. Open research data from POLYPHEM will be useful to other researchers to underpin scientific publications by referring to the POLYPHEM results in surveys or by incorporating the POLYPHEM results in comparative analysis with their own project results. More detailed description of the data and whom they might be useful to will be given later in updated versions of the Data Management Plan, since data collection and creation is an ongoing process.
Data utility. The data generated in EMPOWER will be useful for the project (consortium), for other research projects in a similar field and for companies that want to develop products or systems of a similar nature. Nevertheless, many data generated in this project are subject to intellectual property rights or are part of confidential deliverables and therefore cannot be published. However, data published in public deliverables are made freely available if there is consent of all project partners.
